Global Interventional Oncology Market Anticipates Explosive Growth, Forecasted at $8.06 Billion by 2034 - Regional Insights for Products, Cancer Types, and End-users
12 mars 2024 12h39 HE
|
Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Global Interventional Oncology Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global...
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
12 déc. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings ...
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
07 nov. 2023 16h05 HE
|
Onconova Therapeutics, Inc.
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
02 nov. 2023 10h37 HE
|
Onconova Therapeutics, Inc.
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE...
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
19 oct. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023Additional studies support broad potential, especially in cyclin-dependent cancers NEWTOWN, Pa., Oct. 19, 2023 (GLOBE...
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
14 juin 2023 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
19 avr. 2023 09h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., April 19, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma
14 janv. 2019 16h15 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Jan. 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting
01 déc. 2018 15h45 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Dec. 01, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...